BioMimetic Therapeutics, Inc. To Report First Quarter 2012 Financial Results On May 9
BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the
Company plans to release its financial results for the three months
ended March 31, 2012, on Wednesday, May 9
th after the close
BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company plans to release its financial results for the three months ended March 31, 2012, on Wednesday, May 9 th after the close of market. The Company will host a conference call and audio webcast to discuss its first quarter financial results, product development programs and business activities at 4:30 p.m. EDT the same day. The conference call may be accessed on May 9, 2012 by dialing (877) 224 - 4059 for U.S. and Canadian callers (passcode: 78229094). The international dial in number is (706) 902 - 2069, and the same passcode applies. Participants should dial in 10 minutes prior to the call. A live webcast of the conference call will be available on the Investor Relations section of BioMimetic’s website at www.biomimetics.com. The webcast will be archived for at least 30 days following the call. About BioMimetic Therapeutics BioMimetic Therapeutics (NASDAQ: BMTI) is a biotechnology company specializing in the development and commercialization of clinically proven products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedics, sports medicine and spine applications. All Augment ® branded products are based upon recombinant human platelet-derived growth factor (rhPDGF-BB), which is an engineered form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. Through the commercialization of this patented technology, BioMimetic seeks to become the leading company in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments. BioMimetic has received regulatory approvals to market Augment ® Bone Graft in Canada, Australia and New Zealand for use in hindfoot and ankle fusion indications. Augment is pending regulatory decisions in the U.S. and European Union for similar indications. The Company also markets a bone graft substitute line of products for orthopedic indications called Augmatrix TM Biocomposite Bone Graft. For further information contact Kearstin Patterson, senior director of corporate communications, at 615-236-4419.